AstraZeneca's Breakthrough in IgAN Treatment: Ultomiris Triumphs in Phase III Trials
AstraZeneca PLC announced the successful completion of Phase III trials for Ultomiris, achieving the primary endpoint by significantly reducing proteinuria in IgAN patients. The safety profile aligned with existing knowledge, and no new safety concerns emerged. The change in eGFR measurement will continue until week 106.
AstraZeneca PLC has made a significant breakthrough in the treatment of IgA nephropathy, commonly known as IgAN, with its drug Ultomiris successfully meeting the primary endpoint in Phase III interim analysis trials, held at week 34.
The trial results highlighted a substantial reduction in proteinuria, marking an important milestone for patients dealing with this kidney condition. AstraZeneca confirmed that the observed safety profile of Ultomiris was consistent with prior trials, with no new safety concerns identified.
The ongoing analysis in this trial will extend to week 106, to further evaluate changes in eGFR, ensuring comprehensive assessment of Ultomiris’ effectiveness and safety for future clinical use.
Google News